These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38551711)

  • 21. Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman.
    Fließer EE; Korsten P; Koziolek MJ; Niewold TB; Patschan D; Müller GA; Patschan SA
    Lupus; 2013 Dec; 22(14):1523-5. PubMed ID: 24014569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of belimumab therapy for patients with lupus nephritis: A meta-analysis and a propensity score-matched case-control study.
    Zhang K; Qi T; Guo D; Liu Y
    Immun Inflamm Dis; 2023 Jul; 11(7):e954. PubMed ID: 37506137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
    Jones A; Muller P; Dore CJ; Ikeji F; Caverly E; Chowdhury K; Isenberg DA; Gordon C; Ehrenstein MR
    BMJ Open; 2019 Dec; 9(12):e032569. PubMed ID: 31848169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial.
    Brunner HI; Abud-Mendoza C; Viola DO; Calvo Penades I; Levy D; Anton J; Calderon JE; Chasnyk VG; Ferrandiz MA; Keltsev V; Paz Gastanaga ME; Shishov M; Boteanu AL; Henrickson M; Bass D; Clark K; Hammer A; Ji BN; Nino A; Roth DA; Struemper H; Wang ML; Martini A; Lovell D; Ruperto N;
    Ann Rheum Dis; 2020 Oct; 79(10):1340-1348. PubMed ID: 32699034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient).
    Binda V; Trezzi B; Del Papa N; Beretta L; Frontini G; Porata G; Fabbrini P; Pozzi MR; Messa P; Sinico RA; Moroni G
    J Nephrol; 2020 Oct; 33(5):1019-1025. PubMed ID: 32002799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
    Rovin BH; Furie R; Teng YKO; Contreras G; Malvar A; Yu X; Ji B; Green Y; Gonzalez-Rivera T; Bass D; Gilbride J; Tang CH; Roth DA
    Kidney Int; 2022 Feb; 101(2):403-413. PubMed ID: 34560137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.
    Mysler EF; Spindler AJ; Guzman R; Bijl M; Jayne D; Furie RA; Houssiau FA; Drappa J; Close D; Maciuca R; Rao K; Shahdad S; Brunetta P
    Arthritis Rheum; 2013 Sep; 65(9):2368-79. PubMed ID: 23740801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States.
    Mandrik O; Fotheringham J; Ren S; Tice JA; Chapman RH; Stevenson MD; Pearson SD; Herron-Smith S; Agboola F; Thokala P
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):385-394. PubMed ID: 35115304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 10 Years of belimumab experience: What have we learnt?
    Levy RA; Gonzalez-Rivera T; Khamashta M; Fox NL; Jones-Leone A; Rubin B; Burriss SW; Gairy K; Maurik AV; Roth DA
    Lupus; 2021 Oct; 30(11):1705-1721. PubMed ID: 34238087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.
    Struemper H; Thapar M; Roth D
    Clin Pharmacokinet; 2018 Jun; 57(6):717-728. PubMed ID: 28887801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.
    Sciascia S; Radin M; Yazdany J; Levy RA; Roccatello D; Dall'Era M; Cuadrado MJ
    Autoimmun Rev; 2017 Mar; 16(3):287-293. PubMed ID: 28147262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis.
    Zhang H; Chen J; Zhang Y; Zhao N; Xu D
    Ren Fail; 2023 Dec; 45(1):2207671. PubMed ID: 37194710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
    Schwarting A; Dooley MA; Roth DA; Edwards L; Thompson A; Wilson B
    Lupus; 2016 Dec; 25(14):1587-1596. PubMed ID: 27488472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
    Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
    Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.
    Wallace DJ; Ginzler EM; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Petri M; Fettiplace J; Roth DA; Ji B; Heath A
    Arthritis Rheumatol; 2019 Jul; 71(7):1125-1134. PubMed ID: 30771238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review.
    Margiotta DPE; Basta F; Batani V; Afeltra A
    BMC Nephrol; 2018 Mar; 19(1):54. PubMed ID: 29514612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Belimumab for the treatment of pediatric patients with lupus nephritis.
    Stohl W; Kwok A
    Expert Opin Biol Ther; 2023 Mar; 23(3):243-251. PubMed ID: 36750049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases.
    de la Rubia Navarro M; Ivorra Cortés JR; Grau García E; Román Ivorra JA
    Med Clin (Barc); 2022 Oct; 159(7):344-346. PubMed ID: 35811138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.